COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

Randomized Study of Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab in Pts w/ CLL

The purpose of this research study is to compare the effectiveness of two combinations of anticancer study drugs in treating your Chronic Lymphocytic Leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. The aim is to determine which combination of study drugs is more effective in controlling your specific type of cancer,

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Deborah Stephens
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Leukemia, Lymphoma)

IRB Number

24-0196

ClinicalTrials.gov

NCT06073821

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.